Effects of Delayed Treatment With Combined GDNF and Continuous Electrical Stimulation on Spiral Ganglion Cell Survival in Deafened Guinea Pigs

Verena Scheper,* Gerrit Paasche, Josef M. Miller, Athanasia Warnecke, Nurdanat Berkingali, Thomas Lenarz, and Timo Stöver

1Department of Otolaryngology, Medical University Hannover, Hannover, Germany
2Kresge Hearing Research Institute, University of Michigan, Ann Arbor, Michigan

Electrical stimulation (ES) of spiral ganglion cells (SGC) via a cochlear implant is the standard treatment for profound sensor neural hearing loss. However, loss of hair cells as the morphological correlate of sensor neural hearing loss leads to deafferentation and death of SGC. Although immediate treatment with ES or glial cell line–derived neurotrophic factor (GDNF) can prevent degeneration of SGC, only few studies address the effectiveness of delayed treatment. We hypothesize that both interventions have a synergistic effect and that even delayed treatment would protect SGC. Therefore, an electrode connected to a pump was implanted into the left cochlea of guinea pigs 3 weeks after deafening. The contralateral untreated cochleae served as deafened intraindividual controls. Four groups were set up. Control animals received intracochlear infusion of artificial perilymph (AP/–). The experimental groups consisted of animals treated with AP in addition to continuous ES (AP/ES) or treated with GDNF alone (GDNF/–) or GDNF combined with continuous ES (GDNF/ES). Acoustically and electrically evoked auditory brain stem responses were recorded. All animals were killed 48 days after deafening; their cochleae were histologically evaluated. Survival of SGC increased significantly in the GDNF/– and AP/ES group compared with the AP/– group. A highly significant increase in SGC density was observed in the GDNF/ES group compared with the control group. Additionally, animals in the GDNF/ES group showed reduced EABR thresholds. Thus, delayed treatment with GDNF and ES can protect SGC from degeneration and may improve the benefits of cochlear implants.

Key words: cochlear implant; glial cell line–derived neurotrophic factor; chronic electrical stimulation; delayed treatment

Damage to the sensory cells in the organ of Corti can be caused by various factors, such as noise, drugs, infections, mechanical injury, or aging. After the loss of the sensory epithelium, the downstream auditory neurons, the spiral ganglion cells (SGC), degenerate (Otto et al., 1978; Webster and Webster, 1981; Spoorlin, 1984; Nadol and Hsu, 1991).

The functional state and the number of surviving SGC are among the factors that determine the success of the cochlear implant treatment (Gantz et al., 1993). Deprivation of both excitatory activity and neurotrophic factors (NTF) have been identified as etiological factors for the loss of auditory neurons after deafness (Shepherd et al., 2005). It has been shown that excitation of the auditory nerve by electrical stimulation (ES) greatly reduces the hair cell loss–related degeneration of SGC (Loustau, 1987; Hartshorn et al., 1991; Leake et al., 1991; Mitchell et al., 1997). However, this neuroprotective effect of ES has been objected by other authors (Araki et al., 1998; Shepherd et al., 1994; Li et al., 1999). NTFs, such as neurotrophin-3, glial cell line–derived neurotrophic factor (GDNF), brain–derived neurotrophic factor (BDNF), and ciliary–derived neurotrophic factor, can reduce deafferentation–induced SGC degeneration (Ernfors et al., 1996; Staecker et al., 1996; Miller et al., 1997; Ylikoski et al., 1998; Kuang et al., 1999; Yagi et al., 2000; Shinohara et al., 2002; Nakai-zumi et al., 2004). Simultaneous in vivo treatment of SGC with ES and BDNF (Shepherd et al., 2005) or GDNF transgene delivery from an adenoviral vector (Kanzaki et al., 2002) resulted in a significant enhancement of trophic effects. In these studies, NTF and ES were delivered shortly after deafening, before the onset of SGC degeneration.

Contract grant sponsor: European Union, BIOEAR-project; Contract grant number: QLRT-2001-01563.

*Correspondence to: Verena Scheper, Department of Otolaryngology, Medical University Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. E-mail: Scheper.Verena@MH-Hannover.de

Received 21 April 2008; Revised 10 October 2008; Accepted 13 October 2008

Published online 15 December 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jnr.21964

© 2008 Wiley-Liss, Inc.
The success that can be achieved by the use of cochlear implants is related to the duration of deafness (Tyler and Summerfield, 1996). After the loss of the sensory epithelium, SGC degeneration obviously occurs in two phases with different underlying biomolecular mechanisms. For example, drug-deafened guinea pigs show a significant degeneration of SGC over the first 2 weeks after hair cell loss (Jyung et al., 1989). A further significant degeneration occurs over the ensuing 2 months, leading to a stable neuronal population (approximately 13% of the SGC population of healthy animals; Webster and Webster, 1981; Jyung et al., 1989). Delayed treatment of experimentally deafened guinea pigs with BDNF and ciliary-derived neurotrophic factor axokine-1 (Yamagata et al., 2004) or BDNF and fibroblast growth factor 1 (Miller et al., 2007) beginning after degenerative and apoptotic processes have started increases the survival of SGC. Even delayed ES of the auditory nerve of kittens deafened immediately after birth led to a significant protection of SGC (Leake et al., 1999). It was also shown that delayed ES could rescue SGC (Miller and Altschuler, 1995); however, a higher level of ES was required when compared with the level of ES that is effective immediately after deafness.

To better model the human condition in which considerable degeneration of the SGC population has often already occurred before implantation, the effectiveness of a simultaneous treatment that uses both interventions—ES and GDNF—delayed needs to be assessed. Therefore, we examined for the first time the combined effects of delayed intracochlear application of GDNF (100 ng/ml) and ES on the survival of SGC in systemically deafened guinea pigs. The novel aspect of this study is that experimental treatments were delayed by 3 weeks after deafening, when about 15% of the SGC population (Webster and Webster, 1981; Jyung et al., 1989) are expected to have already degenerated.

MATERIALS AND METHODS

Experimental Subjects

The study was conducted in accordance with the German “Law on Protecting Animals” and with the European Communities Council Directive 86/609/EEC for the protection of animals used for experimental purposes. All experiments were approved by the Institutional Animal Care and Research Advisory Committee at the Medical University Hannover and were permitted by the local government (LAVES, registration 02/558 and 07/1389).

Thirty male pigmented guinea pigs (Charles River WIGA GmbH, Sulzfeld, Germany), weighing between 250 and 450 g, were used in this study. Inclusion criteria were normal hearing thresholds (≤50 dB SPL) assessed by acoustically evoked auditory brain stem response (AABR) and a threshold shift of 60 dB or more after the deafening procedure. All procedures were performed under general anesthesia with xylazine (10 mg/kg, i.m.) and ketamine (40 mg/kg, i.m.). Local prilocaine anesthesia was used for the comfort of the animals.

Normal hearing animals (n = 6) were taken for assessment of SGC perikaryal diameter in nontreated cochleae. The remaining animals (n = 24) were deafened and after 3 weeks divided into four treatment groups. Animals receiving artificial perilymph (AP) alone (AP/− group; n = 7) served as controls. Animals of the AP/ES group (n = 6) received AP in combination with continuous ES. Animals of the GDNF/− group were administered the NTF GDNF (n = 6) alone and of the GDNF/ES group in combination with ES (n = 5).

Deafening Procedure

Animals were chemically deafened on day 0, immediately after the first AABR recording. Single coadministration of the ototoxic agents kanamycin (400 mg/kg, s.c.) and ethacrynic acid (40 mg/kg, i.v.) was used for the systemic deafening. The ethacrynic acid infusion was delayed by 2 hr after kanamycin injection, according to the method described by West et al. (1973). This procedure resulted in complete sensory cell loss and, as a consequence, induction of degeneration processes of the SGC and their nerve fibers. The pattern of SGC degeneration and the density of SGC in the normal guinea pig inner ear have previously been described in detail (Webster and Webster, 1981; Jyung et al., 1989). Deafness was confirmed on day 5/6 as well as on day 21 (just before implantation) by AABR.

AABR

Hearing thresholds were determined and recorded by AABR with the Nicolet Viking IV system (Nicolet Biomedical Inc., Madison, WI). Computer-generated alternating polarity voltage pulses (“click” stimuli) of 100 μsec duration and 10.0 Hz repetition rate were delivered monaurally through a transducer and eartips (polyurethane foam eartips, 13 mm, TIP-300 Tubal Insert Phone, Nicolet Biomedical Inc.) positioned in the external ear canal. To record the neurological responses, subdermal needle electrodes (1.0 M, Nicolet Biomedical) were placed at the vertex (common positive), right and left mastoid (reference), and in the right lower hind limb (ground). Click stimuli from 90 dB SPL decreasing in 10 dB steps (5 dB steps to threshold) were applied. The contralateral ear was masked with white noise 30 dB below stimulus level. The responses were filtered (0.1–3 kHz), amplified, and averaged. Threshold was defined as the lowest click stimulus required to evoke a visually replicable waveform. AABRs were assessed bilaterally on day 0 (before the deafening procedure), on day 5/6, and on day 21 to confirm the success of the deafening procedure.

Surgical Implantation Procedure of the Electrode and the Pump

The electrode–cannula combination (MedEl GmbH, Innsbruck, Austria) consisted of an active electrode, a reference electrode, a percutaneous connector, and a silicone tube (Fig. 1). The active electrode was a Teflon-insulated platinum-iridium wire with 50 μm diameter connected to a single ball contact (250 μm in diameter). The system was cast in silicone that also contained a drug-delivery canal (150 μm diameter). The reference electrode consisted of a Teflon-insulated...
150 μm diameter platinum–iridium wire. A mini osmotic pump (Alzet model 2002; Durect Corp.; infusion rate 0.5 μl/hr, suitable for a 14-day delivery) was connected to the silicone tube and was used for local fluid delivery into the cochlea. In the AP/− group and the AP/ES group, the pumps were filled with AP (145 mM NaCl, 2.7 mM KCl, 2.0 mM MgSO₄, 1.2 mM CaCl₂, 5.0 mM HEPES, 0.1% guinea pig serum albumin). GDNF (Amgen) primed pumps were used for the GDNF/− and the GDNF/ES group (100 ng GDNF dissolved in 1 ml AP). All osmotic pumps were exchanged after 13 days (experimental day 34) to continue infusion of GDNF or AP until experimental day 48.

All deafened guinea pigs were implanted unilaterally (left ear) with the electrode–cannula device (Fig. 1) connected to the mini osmotic pump for direct ES of the auditory nerve and drug delivery into the scala tympani. According to Mitchell et al. (1997), epidural recording electrodes and restraint bolt holding screws were implanted. A subcutaneous pocket between the scapulae was formed to accommodate the pump. The middle ear was exposed, and the round window mem-

**Histological Procedures**

Immediately after EABR recording on day 48, animals were killed by transcardial perfusion with 200 ml of phosphate-buffered saline, followed by 200 ml of 4% glutaraldehyde in phosphate-buffered saline. The temporal bones were removed and the middle ears were examined for infections, tissue reaction, and electrode placement. A hole was cautiously drilled in the apex of the cochlea, and an intrascalar perfusion through the round window with glutaraldehyde was performed. Cochleae were than placed in the fixative for 24 hr at 4°C. After rinsing with 20% trisodium citrate for 1 hr, the cochleae were decalcified in a trisodium citrate–formic acid mixture for 14 days; the solution was changed every day. Cochleae were than dehydrated through a graded series of alcohols (70–100% ethanol). After embedding in paraffin, the cochleae were serially sectioned at 5 μm in a midmodiolar plane. Every section was mounted on a glass slide and stained with hematoxylin and eosin. Midmodiolar sections were used for the quantitative analysis of SGC density because they contain six to seven profiles of Rosenthal’s canal.

We specified the cochlear turns from base to apex as follows: lower and upper basal turn (lb, ub), first middle turn (1.m), second middle turn (2.m), third middle turn (3.m), fourth middle turn (4.m), and apical turn (a) (Fig. 2). Systematic random sampling was used: the first midmodiolar section was randomly selected and then every fifth proximate section was chosen; thus, five most midmodiolar sections were analyzed, each separated by 25 μm. The number of SGC was assessed for each of the six or seven cross-sectional profiles of Rosenthal’s canal on each of the five sections for each cochlea. Perikaryal diameter were assessed from five randomly selected SGC (if available) per Rosenthal’s canal cross section.
The perikaryal diameter was measured nearly parallel to the osseus spiral lamina in the longitudinal axis of the neurons. This axis was easy to discern because the SGC were more oval rather than round (Fig. 4). The measurement and the quantification were performed microscopically at a magnification of 200x (Olympus CKX41, Hamburg, Germany). Images were taken with a CCD camera (Colorview XS, SIS, Muenster, Germany) and processed by an image analysis program (analySIS Version. 3.2, SIS). Only SGC with a minimum perikaryal diameter of 12 µm and a discernible nucleus were counted and included for analysis. The cross-sectional area of each profile of Rosenthal’s canal was determined and was used to calculate the SGC density (cells/10,000 µm²). Both cross-sectional areas of each profile of Rosenthal’s canal and SGC counts were performed in a blinded manner (C.R. and P.E.; see acknowledgment). Because SGC counting and area measurements were not always reliable at the most apical sites, these measurements were combined with the fourth middle turn if available.

Statistical Analysis

All data passed the normality test. The nonparametric Wilcoxon signed ranks test was applied for analysis of the SGC density differences between the treated left side and the untreated right side within the animals of one group. To assess significant differences among the different experimental groups, Bonferroni’s multiple comparison test was used.

RESULTS

AABR and Deafening

Normal hearing animals typically demonstrated an AABR threshold of 35 dB SPL. The application of ototoxic agents (kanamycin and ethacrynic acid) resulted in an AABR threshold shift in all animals of at least 60 dB or more. The success of the deafening procedure is also reflected histologically in a nearly complete loss of both inner and outer hair cells. Figure 2 illustrates the elimination of the organ of Corti observed in each of the treatment groups. The left and the right cochleae of all cohorts showed destroyed hair cells over a distance of more than two turns, from the lower basal turn to the third middle turn. Apical to this level, the damage to the organ of Corti was variable. In the right deafened and untreated cochleae of all groups, the mean SGC density ranged from 2.84 to 3.03 SGC/10,000 µm² (Table I) after 48 days of deafness.

EABR Thresholds

EABRs were recorded on day 21 and weekly throughout the experiment to monitor threshold changes related to the treatment. Representative EABR recordings are shown in Figure 3A,B, evoked from a guinea pig of the GDNF/ES-treated group by various intensities of ES. Figure 3A illustrates the EABR immediately after implantation (day 21), and Figure 3B demonstrates the response on day 48, showing a decrease of thresholds after treatment with GDNF and ES. Figure 3C depicts the EABR threshold changes over the 24-day stimulation period for both electrically stimulated groups (AP/ES, GDNF/ES). All animals treated with GDNF in combination with ES exhibited a decrease of thresholds over the whole study period (48 days) whereas animals from the AP/ES group initially showed an increase of thresholds until day 34, and thereafter a slight decrease. This resulted in an overall increase of EABR thresholds in the AP/ES group (Fig. 3D).

Neuronal Survival

Representative histological sections from all four treatment groups are shown in Figure 4. The SGC survival differed between the treated and untreated control cochleae within one group and between the four experimental groups.

Comparison of the left (treated) side with the right (untreated) side. Spiral ganglion cells (SGCs) were counted in the sections from cochleae of the untreated right ears and from the treated left ears. SGC numbers (mean ± standard deviation [SD]) were com-
TABLE I. Density and Survival in Treated Cochleae Compared With Associated Deafened Side

<table>
<thead>
<tr>
<th>Group</th>
<th>Left, treated side</th>
<th>Right, control side</th>
<th>Difference</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Density (cells/10,000 μm²)</td>
<td>Survival (%)</td>
<td>Density (cells/10,000 μm²)</td>
<td>Survival (%)</td>
</tr>
<tr>
<td>AP/−</td>
<td>2.38</td>
<td>83.80</td>
<td>2.83</td>
<td>100</td>
</tr>
<tr>
<td>AP/ES</td>
<td>3.60</td>
<td>125.87</td>
<td>2.86</td>
<td>100</td>
</tr>
<tr>
<td>GDNF/−</td>
<td>4.09</td>
<td>136.21</td>
<td>3.01</td>
<td>100</td>
</tr>
<tr>
<td>GDNF/ES</td>
<td>5.49</td>
<td>181.18</td>
<td>3.03</td>
<td>100</td>
</tr>
</tbody>
</table>

1Mean spiral ganglion cell (SGC) density and mean SGC survival (experimental ear/control ear × 100) are shown. The SGC density of the control side was considered 100% survival and used for the comparison of SGC survival of the treated side.

*P < 0.05.

**Not significant.

Compared between the left and the right side (Table I). The results showed that delayed administration of GDNF alone or in combination with ES led to a significant increase of the mean SGC density compared with the contralateral untreated right cochlea (4.09 vs. 3.01 SGC/10,000 μm²; 5.49 vs. 3.03 SGC/10,000 μm², respectively; P < 0.01, Table I). Also, combined treatment with AP and ES caused a significant increase in SGC density compared with the deafened right control cochlea (3.60 vs. 2.86 SGC/10,000 μm², P < 0.05). However, animals receiving AP only showed a decrease in SGC density of the implanted left side compared with the untreated right side (approximately −16%).

Comparison of treatment groups. The density of protected SGC is the difference between the density of surviving SGC on the treated (dSGCi) left side and the untreated (dSGCni) right side (dSGCi − dSGCni). We compared the mean density of protected SGC of all four treatment groups (Fig. 5). ES (AP/ES) enhanced the survival of SGC when compared with treatment with AP alone (0.74 vs. −0.45 protected SGC/10,000 μm²; P < 0.05). Infusion of GDNF was even more potent in increasing the number of surviving SGC (1.08 protected SGC in 10,000 μm²; P < 0.01) and appeared to provide greater SGC protection than treatment with ES alone (1.08 vs. 0.74 SGC/10,000 μm²). However, the greatest degree of SGC protection was seen after combined treatment with GDNF and ES (2.46 ± 1.15/10,000 μm²; P < 0.001; Fig. 5; Table I). The protection of SGC achieved by the combined treatment with GDNF and ES was statistically significant when compared with the success achieved when either of the two factors was used alone (P < 0.01 vs. ES; P < 0.05 vs. GDNF).

When subtracting the mean density of protected SGC of the AP/− group from the mean density of protected SGC of the other groups (AP/ES group: 1.19 SGC/10,000 μm²; GDNF/− group: 1.53 SGC/10,000 μm²; GDNF/ES group: 2.91 SGC/10,000 μm²), it is evident that the combined effect after coadministration of GDNF and ES is greater than the sum of effects of the two individual factors (1.19 (AP/ES group) + 1.53 (GDNF/− group) = 2.72). This suggests an interactive synergistic effect of these two survival factors when applied simultaneously.

Basal turn vs. apical turn. Comparison of the SGC survival in the basal turn (lower and upper basal turn + first middle turn) vs. the middle and apical turn (second + third + fourth middle turn + apical turn) of the cochleae of all treatment groups showed a clear difference in SGC survival (Fig. 6). In the GDNF/ES group, the GDNF/− group and the AP/ES group the mean density of protected SGC in the basal turn was higher than in the associated middle and apical turns. This difference is significant in the GDNF/ES cohort (P < 0.05). By contrast, the control cochleae (AP/−) showed a higher SGC density in the middle and apical turns than in the basal turn.

Perikaryal Diameter

Figure 7 depicts the SGC perikaryal diameter for each experimental group of the study and for normal hearing guinea pigs. The perikaryal diameter in the AP/− group was 17.27 ± 1.12 μm. The AP/ES-treated cochleae exhibit a mean perikaryal diameter of 17.79 ± 1.05 μm, whereas SGC in the GDNF/−-treated cochleae were 17.23 ± 0.80 μm, and cells in the GDNF/ES cochleae averaged 17.39 μm ± 1.00 μm SD. No significant differences in soma diameter were observed across the treatment groups. Perikaryal diameter of normal hearing animals were 15.20 ± 0.23 μm and differed statistically significant from the data of the AP/− (P < 0.01), AP/ES (P < 0.001), GDNF (P < 0.05), and GDNF/ES (P < 0.01) groups.

Connective Tissue Growth

Connective tissue growth around the electrode was observed in 17 of 24 implanted cochleae. The tissue formation was variable, ranging from no tissue growth to total filling of the scala tympani (Fig. 2). The tissue reached in some cases from the lower basal turn up to the third middle turn. In contrast to Shepherd et al. (2005), who detected fine fibrous tissue in cochleae treated chronically with BDNF- but not in AP-treated animals, we observed no differences in the growth of connective tissue between the groups.
DISCUSSION

Typically, patients receive their cochlear implant at least 6 months after deafening. It has been shown in animals that within this period a significant loss of SGC has already occurred (Jyung et al., 1989). Although the degeneration of SGC in humans is assumed to be much slower (Otte et al., 1978), a significant loss of SGC may have occurred by the time of cochlear implantation. The benefits that can be achieved by the use of cochlear implants are, among other factors, dependent on the survival and excitability of SGC. Immediate intervention with NTFs and ES may result in enhanced survival and sensitivity of deafferented neural tissue in vivo. However, it is of major importance to investigate whether delayed interventions have a similar efficacy. Recently, it was demonstrated that delayed ES and GDNF/ES may result in enhanced survival and sensitivity of deafferented neural tissue in vivo.

Fig. 3. A, B: Averaged electrophysiological wave forms elicited by varied intensities of ES from an animal of the GDNF/ES group. Display: 1 μV; A: Recordings were made 21 days after deafening. Thresholds were defined on the basis of P III responses (black arrows). The threshold for this subject was defined as 230 μA. B: EABR response of the same animal on day 48. The threshold decreased to 140 μA. C: Mean ± SD changes in EABR thresholds from day 21 to day 48 from animals treated with delayed AP/ES or GDNF/ES. EABR threshold before ES (d21) is displayed as baseline. There are no statistical differences between the two groups. However, the combined GDNF/ES treatment showed a tendency toward a continuous decrease in EABR thresholds throughout the study. By contrast, EABR thresholds displayed an increase in AP/ES-treated animals over time (D).
BDNF application lead to functional and neuroanatomical responses in deafened rats (Song et al., 2008).

The present work examined the functional and anatomical changes induced by a delayed treatment with GDNF (100 ng/ml) and/or ES in deafened guinea pig cochleae. Our results confirm previous studies demonstrating that GDNF and ES alone can increase SGC survival in deafened guinea pigs. Additionally, they also provide evidence of a more than additive effect after combined treatment with GDNF infusion and chronic ES. We demonstrated for the first time that this significant effect of GDNF in combination with ES can be observed even after a treatment delay of 21 days ($P < 0.01$, Fig. 5), when significant degeneration of SGC has already occurred.

SGC Survival in the GDNF Group

According to the suggestions of Jyung et al. (1989) and Webster and Webster (1981), our treatment delay exceeded 14 days to enable the development of significant SGC degeneration. This increased delay between deafening and initiation of treatment was chosen in order to verify that protection of SGC can also be induced with treatment interventions starting once degeneration has already progressed.

Webster and Webster (1981) reported that a combination of kanamycin and ethacrynic acid caused a significant loss of SGC in guinea pigs after 2 weeks. Various studies demonstrated that GDNF application to the inner ear has a protective effect on SGC after deafening. Intracochlear GDNF infusion in noise exposed guinea pigs lead to a significantly enhanced SGC survival when treatment was started 4 days after the deafening procedure (Ylikoski et al., 1998). Marujama and colleagues treated guinea pigs with GDNF 2 days after chemical deafening and observed a neuroprotective effect (Maruyama et al., 2007). Furthermore, adenoviral vector-mediated GDNF application 4–7 days after ototoxic treatment has the ability to rescue SGC from degeneration (Yagi et al., 2000; Kanzaki et al., 2002). Our study corroborates these results and proves the effectiveness of GDNF even after a delayed intervention.

SGC Survival in the ES/AP Group

Miller and Altschuler (1995) showed that ES (200 µA) starting 2 weeks after deafness is effective for SGC protection. We found a significantly increased density of SGC in the electrically stimulated left cochlea when compared with the associated untreated right cochlea ($P < 0.05$, Table I). Furthermore, the density of protected SGC in animals treated with AP/ES differed significantly ($P < 0.05$) from the density of SGC determined in control animals treated only with AP. Thus, continuous ES, delayed by 24 days, still protects SGC from degeneration after hair cell loss.
The earlier the treatment is started after deafening, the higher the survival of SGC that can be achieved. For example, already at 2 days after ototoxic drug treatment, Lousteau (1987) and Hartshorn et al. (1991) stimulated guinea pigs for 1 hr/day for 45 days and for 2 hr/day for 9 weeks, respectively. In both groups, a 50% or higher increase in SGC density in the electrically stimulated cochlea was determined when compared with the deafened untreated side. In contrast, we observed a 25% higher SGC density in stimulated cochleae. The treatment delay is the factor that reduces the number of SGC, and this is consistent with Mitchell et al. (1997), who started ES of guinea pigs 8 days after deafening. They achieved a mean enhancement of SGC survival of 25.7% in stimulated cochleae compared with the deafened untreated cochlea. Thus, ES is an effective means for the protection of the SGC population after deafness, even if initiation of treatment is further delayed.

**SGC Survival in the GDNF/ES Group**

The main goal of this study was to determine the effects of a delayed and combined treatment with GDNF and ES on SGC survival after deafness. The results show that a combination of GDNF and ES is most effective and leads to a highly significant enhancement of SGC density even after a treatment delay of 24 days when compared with the control group. Furthermore, our data demonstrate that this delayed combined therapy protects SGC from degeneration after deafness.
significantly better than either intervention alone, and that this effect is more than additive.

Studies examining the effects of NTF in combination with chronic intracochlear ES on SGC survival have not included GDNF (Shepherd et al., 2005; Song et al., 2008). Only one previous study has investigated the effects of chronically combined GDNF and ES treatment (Kanzaki et al., 2002). By means of viral vector-mediated gene delivery, they demonstrated that the combined treatment with GDNF and ES protects SGC from degeneration after hair cell loss. In that study, continuous ES was provided for 36 days, starting on day 8 after deafening with 100 μA peak, 100 μsec/phase, 250 Hz, and 40% duty cycle. Their results showed that GDNF/ES treatment leads to a statistically significant increase of the mean density of SGC (nearly 11 cells/10,000 μm²) when compared with treatment with GDNF or ES alone (P < 0.05). Our findings demonstrate a similar significant difference between the combined treatment with GDNF/ES and GDNF alone (P < 0.05, Fig. 6). However, we found a highly significant difference when comparing the GDNF/ES and AP/ES groups (P < 0.01). The stimulating parameters are nearly identical in both studies. Therefore, we suggest that the differences in SGC protection between the ES group and the GDNF/ES group are due to the different GDNF application methods. Kanzaki and colleagues (2002) tested the efficacy of GDNF transgene delivery mediated by an adenoviral vector. Adenoviral vectors were used to deliver NTFs to the cochlea; the concentration of the expressed protein can vary. Additionally, adenoviral transfection is known to be unstable (Lu et al., 2005), and a significant decrease of protein expression may be expected over time. With the pump system for delivery of the pure protein, we were able to apply a defined GDNF concentration of 100 ng/ml throughout the whole study period.

**SGC Survival in the Control Group**

Application of AP to deafened cochleae had a negative effect on SGC survival. SGC density decreased in the left cochleae that were treated with AP by approximately 16% when compared with the deafened untreated right cochleae. This indicates that the survival of SGC might be affected by the implantation, the delivery procedure, or the AP itself. This finding is aided by Shepherd et al. (2005), who found lower SGC densities in deafened AP-treated control cochleae when compared with the contralateral untreated deafened ears of the same animal. Another possible explanation could be that NTFs, such as GDNF and artemin, are up-regulated in deafened cochleae (Wissel et al., 2006), but might be diluted by the delivery of AP. This effect could lead to an earlier onset of degeneration.

**Functional Evaluation**

The effects of chronic simultaneous application of NTFs and ES on SGC survival and neural threshold sensitivity in deafened guinea pigs have been examined in two previous studies.

Kanzaki et al. (2002) reported a slight reduction in threshold over time in all treatment groups, declaring that ES alone improves the functional state of existent SGC. In contrast, Shepherd et al. (2005) measured significant reduction of EABR thresholds only when the animals were treated with BDNF, either alone or in combination with ES. Our data corroborate the findings of Shepherd et al. that the combination of NTF intervention and ES reduces the EABR threshold over the treatment period. In contrast to their findings, the AP/ES-treated animals of our study showed a threshold increase only until day 34; thereafter, the thresholds started to decrease. This suggests that the functional effect of the NTF starts immediately after factor application, while ES alone may have a delayed effect on EABR thresholds. The changes in the functional response are reflected in significant differences in the survival of SGC. Both electrically stimulated groups showed an increase in the density of SGC compared with the control group. However, the two GDNF-treated groups (GDNF/ES and GDNF/—) exhibited the greatest effects. These findings indicate again that GDNF is a more effective survival factor than ES for the protection of SGC and the maintenance of electrical excitability after deafness.

**Perikaryal Diameter**

Additional to our data, several previous reports demonstrated that exogenous NTF infusion into the deafened cochlea results in substantial increases in SGC soma size compared with normal hearing cochleae. For example, SGC soma were similar to or greater than those of normal hearing controls after BDNF infusion in guinea pigs (McGuinness and Shepherd, 2005; Shepherd et al., 2005) and significantly larger after infusion of both BDNF and acidic fibroblast growth factor together (Glueckert et al., 2008). Similar increase in neuronal size with GDNF treatment has also been reported, both in vivo (Zhou and Wu, 2006) and in vitro (Anand et al., 2006). However, other authors showed no variation in size of the evaluated cells after GDNF treatment as well (Ducray et al., 2006). Furthermore, Dodson and Mohuiddin (2000) reported an initial increase of soma diameter within the first few weeks after deafness in the untreated groups. The mechanisms underlying an increased soma area after exogenous neurotrophin delivery or deafening remain unclear. Thus, the soma diameter after deafness and/or treatment is controversially discussed in the literature. Further studies are necessary to elucidate these morphological and molecular biological changes in SGC. Therefore, we only used the assessment of SGC diameter to rule out a possible effect of differences in cell size among the experimental groups in the determination of SGC density.
Conclusions

Our results indicate that treatment with GDNF (100 ng/ml) as well as ES (intensity: 8 dB above EABR threshold) delayed by 3 weeks can significantly enhance survival and neurophysiological responsiveness of SGC after ototoxic drug treatment. The novel finding of this study is the highly synergistic trophic and functional effect of the delayed treatment with combined chronic ES and GDNF. Further experiments will be necessary to determine the most effective combination of GDNF concentrations and ES parameters. These investigations may have significant implications for a potential clinical application of a combined treatment with GDNF and ES via a cochlear implant in patients with severe sensorineural hearing loss.

ACKNOWLEDGMENTS

We thank MedEl GmbH for providing the used cochlear implant electrodes and Amgen Inc. for providing the GDNF. We also thank Chris Ellinger for designing and manufacturing the wearable chronic stimulators, and Peter Erfurt and Cornelis Roels for their technical assistance.

REFERENCES


Tyler RS, Summerfield AQ. 1996. Cochlear implantation: relationships with research on auditory deprivation and acclimatization. Ear Hear 17(3 Suppl):38S–50S.


